Medical/Pharmaceuticals
LivFul and Global Access Diagnostics announce partnership for COVID-19 test kit distribution
LIVERPOOL, England, June 9, 2021 /PRNewswire/ -- LivFul and Global Access Diagnostics (GAD) today announced a new partnership to make a variety of diagnostic kits, starting with COVID-19 rapid antigen tests, available in Low to Middle Income Countries. While new innovations are being developed, ...
2021-06-09 10:00
1994
Antengene's Partner Karyopharm Therapeutics Announces Updated Data of Eltanexor in Patients with Hypomethylating Agent Refractory MDS
--Of the 15 patients evaluable for efficacy, 7 (47%) had mCR and 5 (33%) had SD for a total disease control rate of 80%-- --Patients with mCR had longer mOS than patients without mCR or with PD-- SHANGHAI and HONG KONG, June 9, 2021 /PRNewswire/ -- Antengene's Partner, Karyopharm Therapeutics In...
2021-06-09 08:00
3842
Sirtex Medical provides donations to Massachusetts Institute of Technology (MIT) and Brigham and Women's Hospital in support of the Artzi Lab, as part of Sirtex's corporate citizenship strategy to support research and innovation
WOBURN, Mass., June 8, 2021 /PRNewswire/ -- Sirtex Medical (Sirtex), a leading manufacturer of targeted liver cancer therapies, has provided grants to Massachusetts Institute of Technology (MIT) and Brigham and Women's Hospital for the advancement of cancer treatment, to be shared with the indepen...
2021-06-08 20:30
1779
Innoforce Pharmaceuticals to Participate in BIO International Digital Convention
HANGZHOU, China and ROCKVILLE, Md., June 8, 2021 /PRNewswire/ -- Innoforce Pharmaceuticals ("Innoforce"), an innovation and partnership-focused biopharmaceutical company, today announces that the company is participating in the BIO International Digital Convention (BIO Digital) being held fromJun...
2021-06-08 19:00
2692
Neoss Announces NeossONE™ - One Platform, Smart Prosthetics
NeossONE™ is a solution unique to the Neoss® Implant System - one prosthetic platform, across three implant ranges, including ALL implant diameters and abutments. Simply put, the same prosthetic components fit every implant.¹ HARROGATE, England, June 8, 2021 /PRNewswire/ -- ONE Prosthetic Platfo...
2021-06-08 18:15
4335
TargEDys announces the publication of the first double-blind, randomized, placebo-controlled clinical trial showing Hafnia alvei's efficacy at an unprecedented level in weight loss and satiety
LONGJUMEAU, France, June 8, 2021 /PRNewswire/ -- The French biotech TargEDys specialized in breakthrough microbiome-based solutions announces the publication of its study conducted in 230 overweight adults supplemented for 12 weeks, confirming the efficacy of the precision probioticHafnia alvei H...
2021-06-08 16:53
4398
Inspiring Women's Healthcare: Mindray Unveils Nuewa I9, a New OB/GYN Diagnostic Ultrasound System
SHENZHEN, China, June 8, 2021 /PRNewswire/ -- Mindray (SZSE: 300760), a global
leading developer and provider of medical devices and solutions, has introduced
theNuewa I9
2021-06-08 15:37
10237
Copan strengthens its operations in the Americas with a millionaire investment
Copan announces a $78 million investment to expand its Puerto Rican production site. The project – partially financed byPuerto Rico's Government – will bring Copan production and distribution capacity closer to the American market, strengthening the company's presence in the US and the rest of th...
2021-06-08 14:00
3314
Onward Therapeutics Signs an Exclusive Collaboration and Worldwide Option and License Agreement with Institut du Cancer de Montpellier
EPALINGES, Switzerland, June 8, 2021 /PRNewswire/ -- Onward Therapeutics (Onward) and Institut du Cancer de Montpellier (ICM) announced today the execution of an exclusive collaboration and worldwide option and license agreement based on a research program in onco-metabolism being conducted by I...
2021-06-08 12:00
1815
Cytiva opens experience and learning lab in Singapore
* New lab will support Singapore government's Industry 4.0 agenda to build research, digital, innovation capability and talent development * Part of Cytiva's capacity expansion plan to meet the increasing demands for the biopharmaceuticals industry * Through this lab, Cytiva intends to run 7...
2021-06-08 10:00
2276
Innovent Biologics and IASO Biotherapeutics to Present Updated Data from its Anti-BCMA CAR-T Therapy in Relapsed/Refractory Multiple Myeloma at European Hematology Association (EHA) Congress
SAN FRANCISCO and SUZHOU, China, June 8, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2021-06-08 08:00
5543
Live from ASCO 2021 | Ascentage Pharma Delivers Oral Presentation Featuring Updated Data Demonstrating Promising Efficacy and Safety of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Patients with Relapsed or Refractory CLL/SLL
SUZHOU, China, and ROCKVILLE, MD, June 8, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today released updated results from the first...
2021-06-08 07:30
5520
Live from ASCO 2021 | Ascentage Pharma Presents Updated Results of MDM2-p53 Inhibitor Alrizomadlin (APG-115) Demonstrating an ORR of 24.1% Including Complete Response in Combination with Pembrolizumab in Patients with Advanced Melanoma Resistant or Refractory to Prior Immuno-Oncologic Drugs
SUZHOU, China, and ROCKVILLE, Md., June 8, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today presented in an oral presentation at t...
2021-06-08 07:21
12875
ORTHO OPTIX™ Reader Completes Transfusion Medicine Portfolio, Now Available in the United States and Puerto Rico
RARITAN, N.J., June 7, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced its semi-automated ORTHO OPTIX™ Reader, which allows lower-volume transfusion labs to elevate their standard of patient care ...
2021-06-07 21:00
6518
Elekta's new strategy to focus on growth and access to radiation therapy
STOCKHOLM, June 7, 2021 /PRNewswire/ -- At Elekta's (EKTA-B.ST) Capital Markets Day, CEO,Gustaf Salford, and members from his executive management team introduced the company's mid-term strategy, called Access 2025. The strategy reflects the work the company will continue to do to pursue the visi...
2021-06-07 20:44
14184
RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study
The global Phase 2/3 study of orally-administered opaganib for the treatment of severe COVID-19 enrolled a total of 475 patients, more than the planned 464 Opaganib is uniquely positioned as a leading novel, dual-action, investigational COVID-19 oral pill Blinded blended mortality rates encourag...
2021-06-07 19:00
5413
Device Companies will Drive Surgery Automation to Increase Elective Procedures in Western Europe
Western European selective medical devices market for elective procedures is expected to reach$16.8 billion by 2023 at a CAGR of 29.2%, finds Frost & Sullivan SANTA CLARA, Calif., June 7, 2021 /PRNewswire/ -- Frost & Sullivan's recent analysis, Impact of COVID-19 on Elective Procedures in Wester...
2021-06-07 18:02
1874
Elekta and Philips deepen strategic partnership in precise and individualized oncology care
STOCKHOLM and AMSTERDAM, June 7, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) and Royal Philips (NYSE: PHG, AEX: PHIA) today signed agreements to deepen their existing strategic partnership to advance comprehensive and personalized cancer care through precision oncology solutions. The extended collab...
2021-06-07 16:02
6720
Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Plus Paclitaxel/Cisplatin for the First-line Treatment of ESCC at ASCO 2021
SUZHOU, China, June 7, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced data from Phase 2 clinical study (KN046-204) of KN046(PD-L1/CTLA-4 bispecific antibody) plus paclitaxel/cisplatin for the first-line treatment of unresectable locally advanced, recurrent or metastatic e...
2021-06-07 10:11
7221
Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Combined with Chemotherapy for the Treatment of Advanced NSCLC at ASCO 2021
* KN046 combined with platinum doublet chemotherapy is tolerated and has shown promising clinical benefit as IL treatment for stage IV NSCLC. * OS rate at 12 months and 15 months were both 74.9%; Similar survival was observed in patients with PD-L1≥1% and PD-L1<1%; * the median progression-f...
2021-06-07 10:10
6676
Week's Top Stories
Most Reposted
Agoda Opens New Office at One Bangkok, Enhancing Its Technology Hub in Thailand
[Picked up by 321 media titles]
2026-04-09 13:00
Visa Opens the Door to AI-Driven Shopping for Businesses Worldwide
[Picked up by 312 media titles]
2026-04-09 09:00Tata Power Collaborates with Databricks to Build Future-Ready Data and AI Platform to Accelerate Energy Transition
[Picked up by 302 media titles]
2026-04-10 11:13
Hai Robotics and Maersk Redefine Fashion Fulfilment with High-Density Robotics at 10-Metre Scale in Singapore
[Picked up by 292 media titles]
2026-04-14 10:00
iQIYI to Open Its First Central China Theme Park in Wuhan, Continuing to Bring IP Value Beyond the Screen
[Picked up by 288 media titles]
2026-04-10 11:38
Most Read
Agoda Opens New Office at One Bangkok, Enhancing Its Technology Hub in Thailand
2026-04-09 13:00
8019
NYSE Content Update: Starfish Space Adds Over $100 Million in Funding to Boost Growth
2026-04-07 21:06
7604
Visa Opens the Door to AI-Driven Shopping for Businesses Worldwide
2026-04-09 09:00
7505